BRIEF-Traws Pharma Provides Updated Guidance On Influenza Prophylaxis Program

Traws Pharma, Inc.

Traws Pharma, Inc.

TRAW

0.00

June 22 (Reuters) - Traws Pharma Inc TRAW.O:

  • TRAWS PHARMA PROVIDES UPDATED GUIDANCE ON INFLUENZA PROPHYLAXIS PROGRAM

  • TRAWS PHARMA - PREPARING UPDATED TOXICOLOGY DATA FOR MHRA TIVOXAVIR MARBOXIL PHASE 2A STUDY

  • TRAWS PHARMA - UPDATED DATA PACKAGE TO BE RESUBMITTED TO MHRA IN Q3 2026

  • TRAWS PHARMA - COMPANY EXPECTS MHRA RESPONSE WITHIN 30 DAYS OF RESUBMISSION

  • TRAWS PHARMA - COMPANY TO INITIATE PROFILING OF ADDITIONAL MOLECULES FOR INFLUENZA TREATMENT PROGRAM

Source text: ID:nGNXbMtG2x

Further company coverage: TRAW.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.